CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CLYM CLIMB BIO INC

交易中 02-11 14:10:36 EST

5.43

-0.07

-1.36%

最高5.58	最低5.08	成交量22.01万
今开5.50	昨收5.50	日振幅9.00%
总市值2.59亿	流通市值1.67亿	总股本4,774万
成交额116.10万	换手率0.72%	流通股本3,075万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":5.425,"timestamp":1770837011840,"preClose":5.5,"halted":0,"volume":220117,"delay":0,"changeRate":-0.013636363636363669,"floatShares":30748027,"shares":47744400,"eps":-0.75067,"marketStatus":"交易中","change":-0.075,"latestTime":"02-11 14:10:36 EST","open":5.5,"high":5.575,"low":5.08,"amount":1160990.2995612002,"amplitude":0.09,"askPrice":5.44,"askSize":100,"bidPrice":5.41,"bidSize":374,"shortable":3,"etf":0,"ttmEps":-0.75067,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":5.5,"preHourTrading":{"tag":"盘前","latestPrice":5.3925,"preClose":5.5,"latestTime":"08:00 EST","volume":537,"amount":2900.6450769000003,"timestamp":1770814808117,"change":-0.1075,"changeRate":-0.019545,"amplitude":0.045455},"postHourTrading":{"tag":"盘后","latestPrice":5.5,"preClose":5.5,"latestTime":"19:17 EST","volume":2311,"amount":12710.05,"timestamp":1770769063288,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.448921,"impliedVol":4.5038,"impliedVolPercentile":0.8},"requestUrl":"/m/hq/s/CLYM","defaultTab":"news","newsList":[{"id":"1117014745","title":"CLIMB BIO INC：Budoprutug Prismn二期PMN试验完成首例患者给药，初步数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1117014745","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117014745?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:04","pubTimestamp":1767873896,"startTime":"0","endTime":"0","summary":"CLIMB BIO INC宣布，其针对PMN（进行性多发性神经病）的Budoprutug Prismn二期临床试验已完成首例患者给药。该试验旨在评估候选药物的安全性与有效性，预计将于2026年下半年获得初步研究数据。这一里程碑标志着公司在神经疾病治疗领域的研发推进取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2601186879","title":"Climb Bio, Inc.盘中异动 早盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186879?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:04","pubTimestamp":1767625482,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日23时04分，Climb Bio, Inc.股票出现异动，股价大幅跳水5.07%。截至发稿，该股报3.56美元/股，成交量16.0404万股，换手率0.24%，振幅7.15%。Climb Bio, Inc.股票所在的生物技术行业中，整体跌幅为1.48%。Climb Bio, Inc.公司简介：Climb Bio Inc是一家临床阶段的生物技术公司，为免疫介导性疾病患者开发治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105230442953c04f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105230442953c04f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"1182063019","title":"CLIMB BIO INC：无需就布多普鲁替格研发向Alumis支付里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1182063019","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182063019?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:16","pubTimestamp":1767215781,"startTime":"0","endTime":"0","summary":"CLIMB BIO INC（简称：CLYM）正式声明，公司不应承担Alumis就其研发药物布多普鲁替格（Budoprutug）所追索的里程碑付款义务。这一立场凸显了双方在合作协议条款理解上的根本分歧。\n目前，CLIMB BIO INC正全力推进布多普鲁替格的临床开发进程。公司强调，其所有财务义务均严格遵循既有合同约定，不存在Alumis所主张的付款责任。此次争议的解决将直接影响后续研发资源的配置与合作伙伴关系的走向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"1197140729","title":"Climb Bio公司就2024年1月11日资产购买协议纠纷提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=1197140729","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197140729?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:15","pubTimestamp":1767215711,"startTime":"0","endTime":"0","summary":"生物技术企业Climb Bio Inc（股票代码：CLYM）近日因资产收购协议争议正式向法院提交诉状。该协议签署于2024年1月11日，涉及核心资产交易条款的履行分歧。诉讼文件显示，双方对协议中约定的权利义务存在实质性认知差异，可能影响公司后续业务整合进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2593435400","title":"Climb Bio, Inc.盘中异动 股价大涨5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593435400","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593435400?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:31","pubTimestamp":1766413863,"startTime":"0","endTime":"0","summary":"北京时间2025年12月22日22时31分，Climb Bio, Inc.股票出现波动，股价快速拉升5.61%。Climb Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Psyence Biomedical Ltd C/Wts 25/01/2029、Equillium, Inc.、Quantum Biopharma Ltd.涨幅较大，Pmgc Holdings Inc.、Psyence Biomedical Ltd.、Gt Biopharma, Inc.较为活跃，换手率分别为112.17%、15.05%、7.48%，振幅较大的相关个股有Novabay Pharmaceuticals, Inc.、Quantum Biopharma Ltd.、Gain Therapeutics, Inc.，振幅分别为9.31%、6.97%、6.53%。Climb Bio, Inc.公司简介：Climb Bio Inc是一家临床阶段的生物技术公司，为免疫介导性疾病患者开发治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222223103a46ae0ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222223103a46ae0ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"1191476710","title":"新闻稿：Climb Bio 根据纳斯达克上市规则 5635(c)(4) 报告激励股票奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1191476710","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191476710?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:07","pubTimestamp":1764072421,"startTime":"0","endTime":"0","summary":"美国马萨诸塞州韦尔斯利山，2025年11月25日-- Climb Bio, Inc.，一家开发针对免疫介导疾病的治疗药物的临床阶段生物技术公司，今天宣布，Climb Bio 根据其2025年修订的激励计划，向一名新员工授予了激励股票奖励，以激励该名员工与 Climb Bio 签署雇佣合同，符合纳斯达克上市规则 5635。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","BK4139","NQmain","CLYM","BK4539","PSQ","QLD","USAW.SI",".IXIC","USJW.SI","TSYW.SI","QQQ","TQQQ","SQQQ","NVIW.SI","QID"],"gpt_icon":1},{"id":"1185490852","title":"CLIMB BIO INC 任命 Adam Villa 为技术运营高级副总裁，Ashley Jones 为人力资源与战略高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1185490852","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185490852?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:02","pubTimestamp":1761044546,"startTime":"0","endTime":"0","summary":"CLIMB BIO INC 任命 Adam Villa 为技术运营高级副总裁，Ashley Jones 为人力资源与战略高级副总裁。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2484991306","title":"Climb Bio, Inc.2024财年第三财季实现净利润-8.90百万美元，同比减少124.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484991306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484991306?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010429,"startTime":"0","endTime":"0","summary":"11月19日，Climb Bio, Inc.公布财报，公告显示公司2024财年第三财季净利润为-8.90百万美元，同比减少124.18%；其中营业收入为0.00美元，每股基本收益为-0.13美元。从资产负债表来看，Climb Bio, Inc.总负债3.42百万美元，其中短期债务58000.00美元，资产负债比为0.65，流动比率为0.58。机构评级：截至2024年11月19日，当前有2家机构对Climb Bio, Inc.目标价做出预测，其中目标均价为4.50美元，其中最低目标价为4.00美元，最高目标价为5.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180146a24562b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180146a24562b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLYM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":0.068},{"period":"1month","weight":0.0934},{"period":"3month","weight":1.8646},{"period":"6month","weight":2.1977},{"period":"1year","weight":2.481},{"period":"ytd","weight":0.375}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Climb Bio, Inc.于2018年10月18日作为特拉华州公司注册成立。该公司是一家生物技术公司，专注于开发神经元兴奋性障碍的新疗法，以解决精神病学、癫痫、慢性疼痛以及外周和中枢神经系统疾病方面未满足的需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":0.014763},{"month":3,"riseRate":0.25,"avgChangeRate":-0.102291},{"month":4,"riseRate":0.75,"avgChangeRate":0.286337},{"month":5,"riseRate":0.5,"avgChangeRate":0.027501},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069889},{"month":7,"riseRate":0.75,"avgChangeRate":0.07628},{"month":8,"riseRate":0.25,"avgChangeRate":0.096778},{"month":9,"riseRate":0.2,"avgChangeRate":-0.124516},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CLIMB BIO INC(CLYM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CLIMB BIO INC(CLYM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}